School prepares students for careers in medicine, tech

by Elizabeth Baier, Minnesota Public Radio

September 18, 2012

Audio player code:

ROCHESTER, Minn. Zakaria Mahamed wants to go to college and become a pediatrician, training he hopes will someday land him at the Mayo Clinic.

"When I see my family doctor, it makes me feel like I could be there one day," he said. "I could help these kids, I could find new cures for diseases, I can make a difference in my community."

But first, Mahamed has to make it through high school. The 11th grader thinks his chances of doing so are much better at the STEM Academy in Rochester, a charter school that aims to prepare immigrant and minority students for fields such as microbiology, nursing and engineering.

Inside the STEM Academy, teenage girls wear colorful hijabs on their heads and groups of boys speak Somali as they make their way to science, engineering and math classes. Nearly all of the 60 students are Somali-American.

Some are betting the school, in its second year, will help students who struggle in traditional schools find careers to build successful futures.

Mahamed is among them. Born in Rochester to Somali parents, he finished ninth grade at one of Rochester's traditional high schools before transferring to the math and science-focused school.

"When you're in a regular big school that doesn't have a small environment, everything is like you don't have enough time to talk and you'll never meet anybody," he said. "But here, you'll talk to everybody, you know everybody, everyone knows you, you know them."

Link:
School prepares students for careers in medicine, tech

Viruses not to blame for chronic fatigue syndrome after all

Public release date: 18-Sep-2012 [ | E-mail | Share ]

Contact: Jim Sliwa jsliwa@asmusa.org 202-942-9297 American Society for Microbiology

Contrary to previous findings, new research finds no link between chronic fatigue syndrome and the viruses XMRV (xenotropic murine leukemia virus-related virus) and pMLV (polytropic murine leukemia virus). A study to be published on September 18 in mBio, the online open-access journal of the American Society for Microbiology, reveals that research that reported patients with chronic fatigue syndrome carried these two viruses was wrong and that there is still no evidence for an infectious cause behind chronic fatigue syndrome.

"The bottom line is we found no evidence of infection with XMRV and pMLV. These results refute any correlation between these agents and disease," says Ian Lipkin of Columbia University, a co-author on the study.

Chronic fatigue syndrome (CFS), also known as myalgic encephalomyelitis (ME), is a disabling condition in which sufferers experience persistent and unexplained fatigue as well as any of a host of associated problems, including muscle weakness, pain, impaired memory, and disordered sleep. Medical treatment for CFS/ME costs as much as $7 billion every year in the U.S. alone.

The possible causes of CFS/ME have been argued and researched for years with no success. Results from separate studies in 2009 and 2010 that reported finding retroviruses in the blood of patients with CFS/ME created a sensation among patients and the medical community and offered hope that a tractable cause for this disease had finally been found. Since then, other investigators have been unable to replicate the results of those studies, casting doubt on the idea that these viruses, XMRV and pMLV, could be behind CFS/ME.

Lipkin says the National Institutes of Health wanted conclusive answers about the possible link. "We went ahead and set up a study to test this thing once and for all and determine whether we could find footprints of these viruses in people with chronic fatigue syndrome or in healthy controls," says Lipkin. The study in mBio puts the speculation to rest, he says. Scientists were wrong about a potential link between chronic fatigue syndrome and these viruses.

The study authors recruited almost 300 people, 147 patients with CFS/ME and 146 people without the syndrome, to participate. Researchers tested blood drawn from these subjects for the presence of genes specific to the viruses XMRV and pMLV, much in the way the earlier studies had done. But in this study, researchers took extraordinary care to eliminate contamination in the enzyme mixtures and chemicals used for testing, which may have been the source of viruses and genes detected in the earlier studies. XMRV and pMLV are commonly found in mice but there has never been a confirmed case of human infection with these viruses.

The authors of this study include many of the authors of the original papers that reported finding XMRV and pMLV in the blood of CFS/ME patients. This is an important point, says Lipkin, as their participation should lend credibility to the pre-eminence of these newer results over the flawed earlier studies, which offered a certain amount of false hope to the CFS/ME community.

Research on the causes of CFS/ME will continue, says Lipkin. "We've tested the XMRV/pMLV hypothesis and found it wanting," he says. But, he says, "we are not abandoning the patients. We are not abandoning the science. The controversy brought a new focus that will drive efforts to understand CFS/ME and lead to improvements in diagnosis, prevention and treatment of this syndrome."

Visit link:
Viruses not to blame for chronic fatigue syndrome after all

Research and Markets: Future Horizons in the US Microbiology Market: Supplier Shares and Sales Forecasts for 100 …

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/nngc8m/future_horizons) has announced the addition of the "Future Horizons in the US Microbiology Market: Supplier Shares and Sales Forecasts for 100 Infectious Disease Tests by Market Segment" report to their offering.

Highlights

- Comprehensive 1,037-page analysis of the US microbiology testing market.

- Major issues pertaining to the US microbiology laboratory practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the next ten years.

- Current scientific views on the definition, epidemiology, and etiology of major infectious diseases and microorganisms.

- Ten-year test volume and sales forecasts for nearly 80 microbiology tests performed in US hospitals, blood banks, physician offices, public health and commercial laboratories.

- Instrumentation technologies and feature comparison of leading analyzers.

- Sales and market shares of leading suppliers.

- Emerging diagnostic technologies and their potential market applications.

Visit link:
Research and Markets: Future Horizons in the US Microbiology Market: Supplier Shares and Sales Forecasts for 100 ...

The risks of antibiotic resistance and consumption: learning with hands-on activities

ScienceDaily (Sep. 14, 2012) An innovative laboratory-based summer project -- Microbiology recipes: antibiotics la carte -- addressing antibiotic resistance and natural antibiotics has been shown to be an effective strategy to increase high school students' awareness of antibiotic resistance and the relevance of rational antibiotic use. In contrast to traditional educational interventions, which mainly rely on large-scale information campaigns, this project's instructional design was devised to take advantage of the acknowledged benefits of laboratory work, by encouraging the participants' active engagement in their learning.

The study is presented by a group of researchers from the University of Porto, Portugal in the latest issue of PLOS ONE.

Microbiology recipes: antibiotics la carte is a one-week long inquiry-based summer project implemented in the scope of Porto's Junior University -- a summer school-based initiative fostered by the University of Porto, which seeks to promote Science & Technology, Arts, Humanities and Sports education amongst elementary and high school students (aged 11 to 17). Each year, the University's Faculties open their doors to approximately 5000 students, who are invited to take part in a wide range of projects designed by university lecturers and implemented by undergraduate and graduate students in a relaxed, but didactically-focused environment.

The widespread of bacterial resistance to antibiotics is a major public health issue that demands concerted educational interventions to raise public awareness and promote judicious antibiotic use. Consistently with this perceived need, several educational programs have been put forth and numerous didactic resources have been developed. However, reliable indicators of the efficacy of most of these resources have not been consistently provided so far. Furthermore, studies reveal that the general public remains unaware of basic aspects related to the modes of action of antibiotics and frequently engage in misinformed behaviors.

Considering that educational programs targeting young people can contribute to a future generation of scientifically literate antibiotic users, the group of researchers from the University of Porto developed, implemented and assessed a hands-on interventional program to raise young people's interest and consciousness about the consequences of antibiotic resistance and foster their sense of self-responsibility in this regard. Maria Joo Fonseca, one of the researchers involved in the study says "we were interested in sparking students' interest, and scaffolding their scientific reasoning about the processes involved in antibiotic resistance and natural antibiotics' activity, by prompting the connection between observable phenomena and the underlying ideas. We found that, by combining diverse activities, ranging from bioinformatics exercises to natural antibiotic testing, it was possible to address misconceptions, improve students' understanding and promote the development of procedural skills." Fernando Tavares, the coordinator of the project, adds "this study evidences the benefits of incorporating hands-on activities in science education programs. We believe that the data gathered illustrate how an informal educational environment such as the one provided by the Junior University can have a measurable and effective impact on our students, and contribute to promote scientific literacy about pressing socio-scientific issues amongst future generations."

Share this story on Facebook, Twitter, and Google:

Other social bookmarking and sharing tools:

Story Source:

The above story is reprinted from materials provided by IBMC.INEB Associate Laboratory, via AlphaGalileo.

Note: Materials may be edited for content and length. For further information, please contact the source cited above.

Read this article:
The risks of antibiotic resistance and consumption: learning with hands-on activities

Research and Markets: Future Horizons in the Global Infectious Disease Testing Market: Supplier Shares and Sales …

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/dztlbt/future_horizons_in) has announced the addition of the "Future Horizons in the Global Infectious Disease Testing Market: Supplier Shares and Sales Forecasts for 100 Tests by Country" report to their offering.

This comprehensive seven-country report is designed to assist diagnostics industry executives, as well as companies planning to diversify into the dynamic and rapidly expanding microbiology testing market, in evaluating emerging opportunities and developing effective business strategies.

The report provides market segmentation analysis of over 90 diseases and viruses in seven countries, assessment of emerging technologies, review of current instrumentation, as well as strategic profiles of leading suppliers and recent market entrants with innovative technologies and products.

Rationale:

The microbiology testing market is one of the most rapidly growing segments of the in vitro diagnostics industry, and the greatest challenge facing suppliers. Among the main driving forces is continuing spread of AIDS, which remains the world's major health threat and a key factor contributing to the rise of opportunistic infections; threat of bioterrorism; advances in molecular diagnostic technologies; and wider availability of immunosuppressive drugs.

Although for some infections the etiology is still a mystery, while for others the causative microorganisms are present in minute concentrations long before the occurrence of first clinical symptoms, recent advances in genetic engineering and detection technologies are creating exciting opportunities for highly sensitive, specific and cost-effective products.

Geographic Coverage:

- France

- Germany

See the rest here:
Research and Markets: Future Horizons in the Global Infectious Disease Testing Market: Supplier Shares and Sales ...

Research and Markets: Future Horizons in the German Microbiology Market: Supplier Shares and Sales Forecasts for 100 …

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/d23jv9/future_horizons_in) has announced the addition of the "Future Horizons in the German Microbiology Market: Supplier Shares and Sales Forecasts for 100 Infectious Disease Tests by Market Segment" report to their offering.

Highlights:

- Comprehensive 983-page analysis of the German microbiology testing market.

- Major issues pertaining to the German microbiology laboratory practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the next ten years.

- Current scientific views on the definition, epidemiology, and etiology of major infectious diseases and microorganisms.

- Ten-year test volume and sales forecasts for nearly 80 microbiology tests performed in German hospitals, blood banks and commercial laboratories.

- Instrumentation technologies and feature comparison of leading analyzers.

- Sales and market shares of leading suppliers.

- Emerging diagnostic technologies and their potential market applications.

View original post here:
Research and Markets: Future Horizons in the German Microbiology Market: Supplier Shares and Sales Forecasts for 100 ...

Research and Markets: Future Horizons in the Global Microbiology Market: Supplier Shares and Sales Forecasts for 100 …

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/glb7m3/future_horizons_in) has announced the addition of the "Future Horizons in the Global Microbiology Market: Supplier Shares and Sales Forecasts for 100 Infectious Disease Tests by Country" report to their offering.

This comprehensive seven-country report is designed to assist diagnostics industry executives, as well as companies planning to diversify into the dynamic and rapidly expanding microbiology testing market, in evaluating emerging opportunities and developing effective business strategies.

The report provides market segmentation analysis of over 90 diseases and viruses in seven countries, assessment of emerging technologies, review of current instrumentation, as well as strategic profiles of leading suppliers and recent market entrants with innovative technologies and products.

Rationale

The microbiology testing market is one of the most rapidly growing segments of the in vitro diagnostics industry, and the greatest challenge facing suppliers. Among the main driving forces is continuing spread of AIDS, which remains the world's major health threat and a key factor contributing to the rise of opportunistic infections; threat of bioterrorism; advances in molecular diagnostic technologies; and wider availability of immuno-suppressive drugs.

Although for some infections the etiology is still a mystery, while for others the causative microorganisms are present in minute concentrations long before the occurrence of first clinical symptoms, recent advances in genetic engineering and detection technologies are creating exciting opportunities for highly sensitive, specific and cost-effective products.

Geographic Coverage

- France

- Germany

Read the rest here:
Research and Markets: Future Horizons in the Global Microbiology Market: Supplier Shares and Sales Forecasts for 100 ...

Pacific Biosciences Appoints Lucy Shapiro, Ph.D. to Board of Directors

MENLO PARK, Calif., Sept. 12, 2012 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (PACB) provider of the PacBio(R)RS High Resolution Genetic Analyzer, today announced that renowned scientist Lucy Shapiro, Ph.D. of Stanford University has joined the Company's Board of Directors.

Dr. Shapiro currently serves as the Virginia and D.K. Ludwig Professor of Cancer Research and the Director of the Beckman Center for Molecular and Genetic Medicine at Stanford University's School of Medicine, where she has been as a faculty member since 1989. Dr. Shapiro is a co-founder and director of Anacor Pharmaceuticals, Inc. In 1989, Dr. Shapiro founded Stanford University's Department of Developmental Biology, and served as its Chairman from 1989 to 1997. Prior to that, Dr. Shapiro served as Chair of the Department of Microbiology and Immunology in the College of Physicians and Surgeons of Columbia University. She received a B.A. from Brooklyn College and a Ph.D. in Molecular Biology from the Albert Einstein College of Medicine.

Dr. Shapiro has received numerous awards and has been elected to the National Academy of Sciences, the American Academy of Microbiology, the American Academy of Arts and Sciences and the Institute of Medicine of the National Academy of Sciences for her work in the fields of molecular biology and microbiology. Dr. Shapiro previously served as a non-executive director of GlaxoSmithKline plc from 2001 to 2006.

"With dramatic changes in population numbers, the global ecology, and human and animal migration, there is increased scientific attention and urgency to the better understanding of pathogenic bacteria and viruses," said Dr. Shapiro. "Discovering the fundamental mechanisms that control these microscopic forms of life is vital for dealing with emerging infectious diseases in today's global village. PacBio's technology provides a window into the world of these bacteria and viruses that was previously inaccessible to the field of microbiology, and I'm excited to join the company's board to help support the company's success in these and other important applications."

Michael Hunkapiller, Chairman and CEO of Pacific Biosciences commented: "Lucy is renowned for her contributions to the fields of developmental biology, molecular biology and genetics, and it is an honor to have a scientist of her caliber join our Board of Directors. She has been a strong supporter of our technology, and we look forward to deepening our relationship and leveraging her expertise in the fields of infectious diseases and cancer research, which are key applications for the PacBio RS."

More information about Pacific Biosciences is available at http://www.pacb.com. You can also follow the company on Twitter: https://twitter.com/pacbio.

About Pacific Biosciences

Pacific Biosciences of California, Inc. (PACB) offers the PacBio(R)RS High Resolution Genetic Analyzer to help scientists solve genetically complex problems. Based on its novel Single Molecule, Real-Time (SMRT(R)) technology, the company's products enable: targeted sequencing to more comprehensively characterize genetic variations; de novo genome assembly to more fully identify, annotate and decipher genomic structures; and DNA base modification identification to help characterize epigenetic regulation and DNA damage. By providing access to genetic information that was previously inaccessible, Pacific Biosciences enables scientists to increase their understanding of biological systems.

View post:
Pacific Biosciences Appoints Lucy Shapiro, Ph.D. to Board of Directors

Research and Markets: Future Horizons in the US Infectious Disease Testing Market: Supplier Shares and Sales Forecasts …

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/hcccqw/future_horizons_in) has announced the addition of the "Future Horizons in the US Infectious Disease Testing Market: Supplier Shares and Sales Forecasts for 100 Tests by Market Segment" report to their offering.

Comprehensive 1,037-page analysis of the US microbiology testing market. Major issues pertaining to the US microbiology laboratory practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the next ten years. Current scientific views on the definition, epidemiology, and etiology of major infectious diseases and microorganisms. Ten-year test volume and sales forecasts for nearly 80 microbiology tests performed in US hospitals, blood banks, physician offices, public health and commercial laboratories. Instrumentation technologies and feature comparison of leading analyzers. Sales and market shares of leading suppliers. Emerging diagnostic technologies and their potential market applications. Product development opportunities. Profiles of current and emerging suppliers, including their sales, market shares, product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements and business strategies. Business opportunities and strategic recommendations for suppliers.

Contains 1,037 pages and 177 tables

Companies Mentioned:

- Abbott

- Affymetrix

- Beckman Coulter/Danaher

- Becton Dickinson

- bioMerieux

See original here:
Research and Markets: Future Horizons in the US Infectious Disease Testing Market: Supplier Shares and Sales Forecasts ...

The Outdoors Hates You: More New Tick-Borne Diseases (ICAAC 1)

This week Im at ICAAC (the Interscience Conference on Antimicrobial Agents and Chemotherapy), a massive infectious-disease and drugs meeting that is sponsored every year by the American Society for Microbiology. ICAAC is an unabashed scary-disease geekgasm, the kind of meeting at which the editor of a major journal tweets from one room, Modern medicine will come to a halt in India because of catastrophic multi-drug resistance while a microbiologist alerts from another: Rat lungworm traced to salads on a Caribbean cruise. Snails had apparently gotten to the greens.

Good times.

Meanwhile, I was learning more about ticks.

The news last week was of a new tick-borne illness recently identified in Missouri, and of how it demonstrates the way that tick-borne infections are under-appreciated by medicine and public health, and even more by the general public. In addition to the new Heartland virus, I mentioned two other tick-borne diseases that had been identified in the past two years.

It turns out, though, that was an under-count. The news Sunday from ICAAC is that tick-related illnesses are even more common than they appear.

Dr. Bobbi Pritt, the laboratory director of the Mayo Clinic in Rochester, Minn., unfolded a disease detective story that started in the summer of 2009 with two men who liked the outdoors, and two astute lab technicians. The men, a 54-year-old and a 23-year-old who had both been out in the woods in Wisconsin, had fevers, fatigue and headaches, and a history of tick bites; the 23-year-old, who had received a lung transplant for cystic fibrosis, was more seriously ill and had to be hospitalized. The technicians noted that the mens disease was most like erlichiosis but the tick that carries that tick-borne illness is not present in the upper Midwest. Months later after the Centers for Disease Control and Prevention had sent a pair of investigators, after involving epidemiologists from the US military who had been studying illness in the residents of bases nationwide, after trapping mice and grinding up hundreds of ticks the group realized they had found a new tick-borne illness. It was an Erlichia though it is so new that it does not yet have a name but it was carried by a tick species that had never been associated with that organism before. Forty-two people have been sickened by it so far. This is not a benign disease, Pritt warned.

Meanwhile, Dr. Peter Krause, a senior research scientist at the Yale schools of medicine and public health, described yet another formerly unknown tick-borne disease, one that is more like Lyme disease but is caused by a newly identified relative of the Lyme organism called Borrelia miyamotoi. The illness that results is a severe and sometimes fatal relapsing fever. But unlike other relapsing fevers already known to occur in the western United States, this one is carried by a different range of tick species: the hard-bodied ticks that are primarily in the eastern US and are responsible for transmitting Lyme, erlichiosis and anaplasmosis. So far, Krause said, this new disease has been most studied in humans in Russia but ticks carrying B. miyamotoi have already been identified in the United States, in ticks and mice in the Northeast and upper Midwest.

Then, Dr. Gary Wormser of New York Medical College warned that a third tick-borne illness, deer tick virus formerly known to affect only deer is now emerging as a human pathogen. Two cases of encephalitis caused by it have been recorded. Wormser described a third, tragic case that he has not yet published: a 77-year-old man from upstate New York who already had several chronic illnesses was bitten by a tick in October 2010, developed a fever and lethargy a month later, slid into a coma and died 8 months later, having never regained consciousness.

Finally, Dr. Barbara Herwaldt of the CDC reminded us that, even if these stories frighten you enough to never leave your house, you are still at risk of a tick-borne disease. To date, 159 people the tip of the iceberg, she said have been diagnosed with the tick-borne illness babesiosis after receiving a blood transfusion. Because of the lag between bite and symptoms, and because the symptoms of babesiosis like all tick-borne diseases could be caused by so many other things, infected donors are not successfully screened out by blood banks. And because there is no FDA-approved test for babesiosis not just a test for blood, but not even a diagnostic test to prove infection in a patient blood banks and even physicians are unable to say with certainly when someone is a risk and should abstain from donating.

Visit link:
The Outdoors Hates You: More New Tick-Borne Diseases (ICAAC 1)

BioMed’s InTrayâ„¢ GC Diagnostic Device Helps Health Providers Comply With New Federal Guidelines to Slow Rise of Drug …

WHITE CITY, Ore., Sept. 6, 2012 /PRNewswire/ --BioMed Diagnostics, Inc., an innovative manufacturer of microbiology devices that facilitate and enhance infectious disease diagnosis, today reported that the unique design of its InTray GC device can help healthcare providers implement new federal guidelines for the treatment of gonorrhea, one of the most common sexually transmitted diseases (STDs.)

The changes announced last month by the Centers for Disease Control and Prevention (CDC) were prompted by evidence that the bacterium that causes gonorrhea is developing resistance to currently-used oral antibiotics. The new guidelines recommend therapy with a more powerful injectible antibiotic and a second antibiotic, along with culture-based retesting to monitor antimicrobial resistance and ensure that the gonorrhea has been cured. Patients whose infections are not fully eradicated are at risk of serious complications and they can continue to spread the disease to others. They may also contribute to development of drug resistance.

BioMed's InTray GC uniquely combines sample collection, transport and culture in a single read-out ready platform, enabling simultaneous detection and observation of the bacterium responsible for gonorrhea. InTray GC reduces handling, increases productivity, improves throughput and reduces the risk of sample exposure and contamination.

The InTray GC system is equipped with an integrated carbon dioxide tablet contained in a sealed inner chamber to prevent degradation during storage. Once the chamber is punctured and the InTray device sealed, the tablet generates the anaerobic atmosphere needed to detect gonorrhea, eliminating the need for costly carbon dioxide incubators.

"The CDC's new guidelines reflect the urgency of ensuring that we track resistance trends so that we continue to have effective treatments for gonorrhea, and infected patients are actually cured," said Jim Self, Chief Executive Officer of BioMed Diagnostics. "Our one-step InTray GC device has demonstrated its utility in everyday clinical use, making it easier and more economical to detect whether a patient is infected and whether the bacterial strain shows resistance. We look forward to working with healthcare providers to demonstrate how InTray GC can help them implement the new diagnostic guidelines efficiently and cost effectively."

Gonorrhea is among the most common STDs, with the CDC estimating that more than 700,000 people in the US acquire new infections each year. If left untreated, gonorrhea can lead to long-term health consequences, including chronic pelvic pain, ectopic pregnancy and infertility. It can also increase the risk of contracting and transmitting HIV.

BioMed devices are listed with the US Food and Drug Administration for in vitro diagnostic use in human clinical laboratories. For more information on InTray GC, visit http://www.biomeddiagnostics.com/ivd-intray-gc/

For information on BioMed Diagnostics' other InTray and InPouch infectious disease devices, visit http://www.biomeddiagnostics.com/clinical.

About BioMed Diagnostics BioMed Diagnostics, Inc. is a manufacturer of in vitro clinical diagnostic, veterinary, environmental and research-only microbiology testing devices that save time and money, improve workflow and throughput, and reduce sample exposure and contamination. By combining sample collection, transport and culture in a single read-out ready platform, BioMed's InPouch and InTray devices help medical professionals, veterinarians, researchers and environmental and industry scientists accurately detect and enumerate a variety of bacterial and fungal pathogens. The devices' unique sealed design reduces the risk of pathogen exposure, and they have a long shelf life. InTray products featuring Colorex technology enable easy-to-interpret visual results from a simple color change. To learn more about BioMed Diagnostics products and services, visit:www.biomeddiagnostics.com.

Read this article:
BioMed's InTrayâ„¢ GC Diagnostic Device Helps Health Providers Comply With New Federal Guidelines to Slow Rise of Drug ...

Q&A: U of Cambridge’s Sharon Peacock on Next-Gen Sequencing for Public Health Surveillance

Name: Sharon Peacock Title: Professor of clinical microbiology, Departments of Medicine and Pathology at the University of Cambridge; Honorary consultant microbiologist at the Health Protection Agency and Cambridge University Hospitals NHS Trust; Honorary faculty at the Wellcome Trust Sanger Institute Education: BS in medicine, University of Southampton; MRCP, Royal College of Physicians, London; MS in medical microbiology, University of London; PhD, Oxford University and Open University Whole-genome sequencing has recently made strides as a tool that can be used in public health surveillance. Most recently, the National Institutes of Health published a study in which they used sequencing in real time during an outbreak to track transmission and make decisions about how to manage the outbreak (CSN 8/20/2012).

Earlier this summer, groups from the UK published studies in the New England Journal of Medicine and BMJ Open, demonstrating the ability of sequencing retrospectively to track MRSA outbreaks in hospitals (CSN 6/20/2012).

Sharon Peacock, an author of the NEJM study, has been making significant gains in bringing whole-genome sequencing into a public health setting.

Under grants from the UK Clinical Research Collaboration and the UK's Health Protection Agency she has been working alongside collaborators, such as Julian Parkhill's team at the Wellcome Trust Sanger Institute and David Aanensen at Imperial College, to develop tools that will enable public health organizations to adopt sequencing for surveillance and diagnostics.

Peacock also published an editorial recently in PLoS Pathogens on the use of sequencing in public health microbiology.

She is currently working within the Cambridge UKCRC consortium to develop databases of pathogen genomes and create interpretation tools for public health organizations, diagnostic laboratories, and health care workers.

Recently, Peacock spoke with Clinical Sequencing News about her work in bringing whole-genome sequencing into clinical microbiology for public health surveillance.

What is the goal of the Cambridge UKCRC consortium?

Our objective is to try and translate whole-genome sequencing into diagnostic and public health microbiology where it's been shown to make a difference either to individual patient care or public health surveillance. At the moment, we're working particularly on [methicillin-resistant Streptococcus aureus], but we're just in the process of expanding this out to a range of other pathogens that are important for human infection.

Can you describe the work that you're doing with MRSA?

Read more:
Q&A: U of Cambridge's Sharon Peacock on Next-Gen Sequencing for Public Health Surveillance

UF to offer STEM degrees in Miami

Community college students in Miami have a chance to earn microbiology degrees from UF without the six-hour drive.

The National Science Foundations undergraduate education division awarded to UF and Miami Dade College last month a $1.7 million grant to increase the number of students graduating with degrees in science, technology, engineering and math.

The foundation is looking for innovative ways to bring community college students, particularly minorities, to bigger universities for life science degrees, said grant writer Eric Triplett, chairman of the UF College of Agricultural and Life Sciences microbiology and cell science department.

[The foundation is] willing for people to take risks, he said.

The grant will expand the distance-learning program UF and Miami Dade faculty launched last Fall. Miami Dade is a full partner in the program, Triplett said.

Miami Dade students who earn an associate of arts degree there and get minimum grades in certain prerequisite courses are eligible for the program.

Almost all the microbiology courses are available online, Triplett said. Miami Dade students can also attend shortened lab sessions on UFs campus.

The five-year grant will fund 20 $1,250 scholarships each semester for students at Miami Dade, Triplett said. About 10 research stipends at UF labs throughout South Florida will also be available.

The grant will also provide career workshops to educate students about job options after graduating with a microbiology degree.

Theres more to life than medical school, Triplett said.

View post:
UF to offer STEM degrees in Miami

Biofuel waste product recycled for electricity

A lab-scale microbial fuel cell, used to study the generation of electricity from waste products. Credit: Lisa Buddrus

A by-product of biofuel manufacture can power microbial fuel cells to generate electricity cheaply and efficiently, according to scientists presenting their work at the Society for General Microbiology's Autumn Conference. The work could help develop self-powered devices that would depollute waste water and be used to survey weather in extreme environments.

Distillers Dried Grain with Solubles (DDGS) is a waste product from bioethanol production that is commonly used as a low-cost animal feed. Researchers from the University of Surrey incorporated DDGS together with bacteria-inoculated sludge from a waste water treatment plant in their microbial fuel cell. The design of the fuel cell meant that the bacteria, which used the DDGS for growth, were physically separated from their oxygen supply. This meant that the bacteria were forced into sending electrons around a circuit leading to a supply of oxygen. By tapping into this electron flow, electricity could be generated from the waste.

Microbial fuel cells offer the ability to convert a wide range of complex organic waste products into electrical energy, making it an attractive target technology for renewable energy. Finding cost-efficient starting products is necessary to help commercialize the process, explained Lisa Buddrus who is carrying out the research. "DDGS is potentially one of the most abundant waste products in the UK. As the biofuel industry expands the supply of DDGS will become more abundant," she said. "The next step for us is to identify the electrogenic bacterial species that grow on DDGS. Furthermore, by looking at genetics across this microbial community, we will be able to better understand the metabolic processes and essential genes involved in electron liberation and transfer." she said.

As well as being low-cost, microbial fuel cells that use DDGS are very environmentally friendly. The waste that is left following electricity extraction is of greater value, as it is less reactive with oxygen, making it less polluting. "We've found something really useful from a waste product without affecting its value as animal feed and at the same time improving its environmental status. This is something we place great importance on and within our group we have a team solely dedicated to reducing polluting potential," said Professor Mike Bushell who is leading the group.

A lot of microbial fuel cell research focuses on developing environmental sensors in remote locations. "Self-powered sensors in remote places such as deserts or oceans can be used to provide important data for monitoring weather or pollution. Other applications in focus for microbial fuel cells include treating waste water to produce green electricity and clean up the water at the same time," explained Professor Bushell.

More information: Ms Buddrus' presentation "Electricity generation in MFCs using distillers' dried grains with solubles" will take place on Wednesday 5 September in session WA058 at the Society for General Microbiology's Autumn Conference 2012.

Provided by Society for General Microbiology

Visit link:
Biofuel waste product recycled for electricity

New long-term antimicrobial catheter developed

Public release date: 3-Sep-2012 [ | E-mail | Share ]

Contact: Laura Udakis l.udakis@sgm.ac.uk 44-079-908-26696 Society for General Microbiology

A novel antimicrobial catheter that remains infection-free for up to twelve weeks could dramatically improve the lives of long-term catheter users. The scientists who have developed the new technology are presenting their work at the Society for General Microbiology's Autumn Conference at the University of Warwick.

Researchers at the University of Nottingham have developed a catheter that can kill most urinary bacteria, including most strains of Proteus bacteria the most common cause of catheter infections. Importantly the antimicrobial catheter retains its activity for between six to twelve weeks, making it suitable for long-term use, unlike existing commercial anti-infection catheters.

Urinary catheters are commonly used to manage incontinence in the elderly or individuals who have suffered long-term spinal cord injury. All catheters become infected after a couple of weeks and Proteus bacteria are responsible for up to 40% of these infections. The bacterium sticks to catheter surfaces and breaks down urea, causing the pH of urine to rise. This causes deposits of mineral crystals in the catheter which blocks it, preventing drainage. If unnoticed, catheter blockage can lead to kidney and bloodstream infections, which ultimately may result in potentially fatal septic shock.

This new antimicrobial catheter has significant advantages over existing solutions, explained Dr Roger Bayston who is leading the development. "Commercial 'anti-infection' catheters are active for only a few days and are not suitable for long-term use. There is an urgent need for an antimicrobial catheter that is suitable for long-term use. Our catheter uses patented technology that does not involve any coatings which extends its antimicrobial activity. The process involves introducing antimicrobial molecules into the catheter material after manufacture, so that they are evenly distributed throughout it, yet can move through the material to replenish those washed away from the surface."

There are 100 million catheter users worldwide whose lives can be severely disrupted by illness from repeat infections and side-effects from antibiotics. "The catheter technology has proven benefit in other medical settings and has the potential to be the solution to recurrent infections in long-term catheter users, which will improve quality of life of these individuals. In addition, reducing the need to frequently change catheters and treat infections would represent huge financial savings to the NHS," explained Dr Bayston.

###

AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.

Read more here:
New long-term antimicrobial catheter developed

Waste cooking oil makes bioplastics cheaper

"Bioplastics" that are naturally synthesized by microbes could be made commercially viable by using waste cooking oil as a starting material. This would reduce environmental contamination and also give high-quality plastics suitable for medical implants, according to scientists presenting their work at the Society for General Microbiology's Autumn Conference at the University of Warwick.

The Polyhydroxyalkanoate (PHA) family of polyesters is synthesized by a wide variety of bacteria as an energy source when their carbon supply is plentiful. Poly 3-hydroxybutyrate (PHB) is the most commonly produced polymer in the PHA family. Currently, growing bacteria in large fermenters to produce high quantities of this bioplastic is expensive because glucose is used as a starting material.

Work by a research team at the University of Wolverhampton suggests that using waste cooking oil as a starting material reduces production costs of the plastic. "Our bioplastic-producing bacterium, Ralstonia eutropha H16, grew much better in oil over 48 hours and consequently produced three times more PHB than when it was grown in glucose," explained Victor Irorere who carried out the research. "Electrospinning experiments, performed in collaboration with researchers from the University of Birmingham, showed that nanofibres of the plastic produced from oils were also less crystalline, which means the plastic is more suited to medical applications."

Previous research has shown that PHB is an attractive polymer for use as a microcapsule for effective drug delivery in cancer therapy and also as medical implants, due to its biodegradability and non-toxic properties. Improved quality of PHB combined with low production costs would enable it to be used more widely.

The disposal of used plastics - which are largely non-biodegradable - is a major environmental issue. Plastic waste on UK beaches has been steadily increasing over the past two decades and now accounts for about 60% of marine debris. "The use of biodegradable plastics such as PHB is encouraged to help reduce environmental contamination. Unfortunately the cost of glucose as a starting material has seriously hampered the commercialization of bioplastics," said Dr Iza Radecka who is leading the research. "Using waste cooking oil is a double benefit for the environment as it enables the production of bioplastics but also reduces environmental contamination caused by disposal of waste oil."

The next challenge for the group is to do appropriate scale-up experiments, to enable the manufacture of bioplastics on an industrial level.

More information: Dr Radecka's poster presentation "Making bioplastic from different oils" will take place on Monday 3 September at the Society for General Microbiology's Autumn Conference 2012.

Provided by Society for General Microbiology

Go here to read the rest:
Waste cooking oil makes bioplastics cheaper

Coconut oil could combat tooth decay

Digested coconut oil is able to attack the bacteria that cause tooth decay. It is a natural antibiotic that could be incorporated into commercial dental care products, say scientists presenting their work at the Society for General Microbiology's Autumn Conference at the University of Warwick.

The team from the Athlone Institute of Technology in Ireland tested the antibacterial action of coconut oil in its natural state and coconut oil that had been treated with enzymes, in a process similar to digestion. The oils were tested against strains of Streptococcus bacteria which are common inhabitants of the mouth. They found that enzyme-modified coconut oil strongly inhibited the growth of most strains of Streptococcus bacteria including Streptococcus mutans an acid-producing bacterium that is a major cause of tooth decay.

Many previous studies have shown that partially digested foodstuffs are active against micro-organisms. Earlier work on enzyme-modified milk showed that it was able to reduce the binding of S. mutans to tooth enamel, which prompted the group to investigate the effect of other enzyme-modified foods on bacteria.

Further work will examine how coconut oil interacts with Streptococcus bacteria at the molecular level and which other strains of harmful bacteria and yeasts it is active against. Additional testing by the group at the Athlone Institute of Technology found that enzyme-modified coconut oil was also harmful to the yeast Candida albicans that can cause thrush.

The researchers suggest that enzyme-modified coconut oil has potential as a marketable antimicrobial which could be of particular interest to the oral healthcare industry. Dr Damien Brady who is leading the research said, "Dental caries is a commonly overlooked health problem affecting 60-90% of children and the majority of adults in industrialized countries. Incorporating enzyme-modified coconut oil into dental hygiene products would be an attractive alternative to chemical additives, particularly as it works at relatively low concentrations. Also, with increasing antibiotic resistance, it is important that we turn our attention to new ways to combat microbial infection."

The work also contributes to our understanding of antibacterial activity in the human gut. "Our data suggests that products of human digestion show antimicrobial activity. This could have implications for how bacteria colonize the cells lining the digestive tract and for overall gut health," explained Dr Brady. "Our research has shown that digested milk protein not only reduced the adherence of harmful bacteria to human intestinal cells but also prevented some of them from gaining entrance into the cell. We are currently researching coconut oil and other enzyme-modified foodstuffs to identify how they interfere with the way bacteria cause illness and disease," he said.

More information: Dr Brady's poster presentation "Inhibition of cariogenic streptococci using enzyme modified coconut oil" will take place on Monday 3 September at the Society for General Microbiology's Autumn Conference 2012.

Provided by Society for General Microbiology

Go here to read the rest:
Coconut oil could combat tooth decay

Bacterial cause found for skin condition rosacea

Scientists are closer to establishing a definitive bacterial cause for the skin condition rosacea. This will allow more targeted, effective treatments to be developed for sufferers, according to a review published in the Journal of Medical Microbiology.

Rosacea is a common dermatological condition that causes reddening and inflammation of the skin mostly around the cheeks, nose and chin. In severe cases skin lesions may form and lead to disfigurement. Rosacea affects around 3% of the population usually fair-skinned females aged 30-50 and particularly those with weak immune systems. The condition is treated with a variety of antibiotics, even though there has never been a well-established bacterial cause.

A new review carried out by the National University of Ireland concludes that rosacea may be triggered by bacteria that live within tiny mites that reside in the skin.

The mite species Demodex folliculorum is worm-like in shape and usually lives harmlessly inside the pilosebaceous unit which surrounds hair follicles of the face. They are normal inhabitants of the face and increase in number with age and skin damage for example, following exposure to sunlight. The numbers of Demodex mites living in the skin of rosacea patients is higher than in normal individuals, which has previously suggested a possible role for the mites in initiating the condition.

More recently, the bacterium Bacillus oleronius was isolated from inside a Demodex mite and was found to produce molecules provoking an immune reaction in rosacea patients. Other studies have shown patients with varying types of rosacea react to the molecules produced by this bacterium exposing it as a likely trigger for the condition. What's more, this bacterium is sensitive to the antibiotics used to treat rosacea.

Dr Kevin Kavanagh who conducted the review explained, "The bacteria live in the digestive tracts of Demodex mites found on the face, in a mutually beneficial relationship. When the mites die, the bacteria are released and leak into surrounding skin tissues - triggering tissue degradation and inflammation."

"Once the numbers of mites increase, so does the number of bacteria, making rosacea more likely to occur. Targeting these bacteria may be a useful way of treating and preventing this condition," said Dr Kavanagh. "Alternatively we could look at controlling the population of Demodex mites in the face. Some pharmaceutical companies are already developing therapies to do this, which represents a novel way of preventing and reversing rosacea, which can be painful and embarrassing for many people."

More information: Dr Kavanagh's review "The potential role of Demodex folliculorum mites and bacteria in the induction of rosacea," will be published online ahead of print on Thursday 30 August in the Society for General Microbiology's Journal of Medical Microbiology. dx.doi.org/10.1099/jmm.0.048090-0

Journal reference: Journal of Medical Microbiology

Provided by Society for General Microbiology

View original post here:
Bacterial cause found for skin condition rosacea

Research and Markets: Food Microbiology: An Introduction, Third Edition Includes Expert Perspectives on Parasites …

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/8kkjwc/food_microbiology) has announced the addition of John Wiley and Sons Ltd's new report "Food Microbiology: An Introduction, Third Edition" to their offering.

Authoritative coverage presented in a format designed to facilitate teaching and learning

The newly updated and expanded third edition:

- Incorporates instructors' input to further clarify complex topics in the field of food microbiology.

- Encourages students to venture beyond memorization and think critically to gain a broader conceptual understanding of food microbiology and acquire the understanding and skills necessary to ensure the safety of tomorrow's food supply.

- Presents explicit learning goals to focus students on the core principles of food microbiology.

- Introduces the genetics and molecular mechanisms important for the understanding of foodborne microbes

Key Topics Covered:

I. Basics of Food Microbiology

See the original post:
Research and Markets: Food Microbiology: An Introduction, Third Edition Includes Expert Perspectives on Parasites ...

Antibiotic residues in sausage meat may promote pathogen survival

Public release date: 28-Aug-2012 [ | E-mail | Share ]

Contact: Jim Sliwa jsliwa@asmusa.org 202-942-9297 American Society for Microbiology

Antibiotic residues in uncured pepperoni or salami meat are potent enough to weaken helpful bacteria that processors add to acidify the sausage to make it safe for consumption, according to a study to be published in mBio, the online open-access journal of the American Society for Microbiology, on August 28.

Sausage manufacturers commonly inoculate sausage meat with lactic-acid-producing bacteria in an effort to control the fermentation process so that the final product is acidic enough to kill pathogens that might have existed in the raw meat. By killing the bacteria that produce lactic acid, antibiotic residues can allow pathogenic bacteria to proliferate.

Researchers at the University of Copenhagen, Denmark, and University College Cork, Ireland, found that antibiotic concentrations within limits set by US and European Union (EU) regulators are high enough to slow fermentation, the process that acidifies the sausages and helps destroy foodborne pathogens like Salmonella or E. coli.

"At low concentrations and at regulatory levels set by authorities, we could see that the lactic acid bacteria are more susceptible to the antibiotics than the pathogens are," says Hanne Ingmer, of the University of Copenhagen, a researcher on the study. "So basically, we can have a situation where residual antibiotics in the meat can prevent or reduce fermentation by the lactic acid bacteria, but these concentrations do not effect survival or even multiplication of pathogens."

Antibiotics used as growth promoters or to treat disease in livestock can eventually end up in meat, and regulators in the US and EU have set limits on the concentrations of antibiotics in meat for consumption by humans. Ingmer and her colleagues set out to determine whether antibiotics falling within statutory limits might interfere with the process of fermentation in products like pepperoni, salami, or chorizo - sausages that are fermented using lactic- acid-producing bacteria in a curing process many cultures have employed for hundreds of years. She says fermented sausages occasionally cause serious bacterial infections, but it's never been understood why that might be.

In small-scale experiments in the lab, Ingmer and her colleagues added the antibiotics oxytetracycline or erythromycin to meat inoculated with lactic-acid-producing bacteria and pathogens Escherichia coli O157:H7 and Salmonella enterica. They followed the progress of the fermentation and tracked the survival of the pathogens. Ingmer says several different starter cultures of lactic-acid-producing bacteria were sensitive to these antibiotics and hence did not acidify the sausage meat effectively - results that could explain why people sometimes get sick from eating fermented sausage.

Ingmer says the results show antibiotics can potentially have a paradoxical effect that would increase the risk of foodborne illness: antibiotic residues reduce the effectiveness of bacteria that should make the sausages safe but don't affect the bacteria that can cause illness.

Although the results raise an alarm for the manufacture of processed meats, Ingmer stresses that it is important to conduct similar tests in manufacturing facilities. "The majority of sausages are manufactured at a commercial scale. It has to be addressed whether this is a problem in a real life facility," Ingmer says.

The rest is here:
Antibiotic residues in sausage meat may promote pathogen survival